Barclays analyst Matt Miksic lowered the firm’s price target on Abbott (ABT) to $143 from $144 and keeps an Overweight rating on the shares. The firm views the company’s Q1 report as mixed but says it is seeing signs of improvement. The share pullback offers a buying opportunity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Reaches Preliminary Settlement in Derivative Governance Case
- Abbott says data at AACR demonstrate advancements in Cancerguard test
- Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings
- Abbott price target lowered to $130 from $135 at RBC Capital
- Abbott price target lowered to $115 from $132 at Oppenheimer